Clinical Trial Update: SPECT Study With SB-773812 In Schizophrenic Patients [Phase 1]

View source ↗

Summary

A Phase 1 SPECT imaging study of SB-773812 in schizophrenia patients was conducted by GlaxoSmithKline. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SB-773812

Snippet

Sponsor: GlaxoSmithKline | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED